Plozasiran, in Phase 2 SHASTA-2 study, significantly reduced triglycerides and APOC3 in severe hypertriglyceridemia patients, supporting further investigation and Phase 3 trials.
Plozasiran, an APOC3-targeted small interfering RNA drug, reduced triglycerides and APOC3 by up to 86% and 90% respectively in patients with severe hypertriglyceridemia, as per the Phase 2 SHASTA-2 study. The study's results support further investigation into the drug's potential to treat severe hypertriglyceridemia. The Phase 3 SHASTA-3 and SHASTA-4 trials will determine if plozasiran can reduce the risk of severe hypertriglyceridemia-associated complications.
April 07, 2024
3 Articles